# US Neuropathic Pain Market

> US Neuropathic Pain Market Research Report: Size, Share, Trend Analysis By Types of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable) and By End Users (Hospitals, Clinics, Home Care) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.76%
- **2024:** $ 1,911 Million
- **2025:** $ 2,040.18 Million
- **2035:** $ 3,926 Million
- **Key Players:** Pfizer Inc (US), Eli Lilly and Company (US), Astellas Pharma Inc (JP), Boehringer Ingelheim GmbH (DE), Teva Pharmaceutical Industries Ltd (IL), Novartis AG (CH), Johnson & Johnson (US), AbbVie Inc (US)

**Report ID:** MRFR/HC/17923-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-neuropathic-pain-market-19470

---

## Market Summary

## **US Neuropathic Pain Market Overview**

As per MRFR analysis, the US Neuropathic Pain Market Size was estimated at 1.5 (USD Billion) in 2023. The US Neuropathic Pain Market Industry is expected to grow from 1.6(USD Billion) in 2024 to 3.1 (USD Billion) by 2035. The US Neuropathic Pain Market CAGR (growth rate) is expected to be around 6.197% during the forecast period (2025 - 2035).

### **Key US Neuropathic Pain Market Trends Highlighted**

The US Neuropathic Pain Market is experiencing significant trends, driven primarily by an increase in the prevalence of neuropathic conditions, propelled by factors such as diabetes and shingles. The rising incidence of these conditions among the aging population in the US is creating a heightened demand for effective treatment options.
 Furthermore, advancements in pharmaceutical research and development are playing a crucial role, as new medications are being introduced that offer improved efficacy and safety profiles. The availability of various therapies, including non-opioid medications, neuromodulators, and innovative delivery systems, is transforming the landscape of pain management.

There are ample opportunities to be explored in the US market, especially with the ongoing research into combination therapies that can enhance patient outcomes. The integration of digital therapeutics and telemedicine is also a growing niche, offering convenience and broader access to care for patients suffering from neuropathic pain. Additionally, awareness efforts aimed at educating both healthcare providers and the public about neuropathic pain can lead to earlier diagnosis and treatment, ultimately improving patient care.

In recent times, there has been a noticeable trend toward personalized medicine, which tailors pain management strategies to the individual patient's needs. This approach is likely to gain more traction in the coming years as healthcare systems adjust to adopt more patient-centric models. Regulatory support for innovative products aimed at pain relief is also increasing, as the US government continues to combat the opioid crisis and seeks safer alternatives for pain management.
 These developments indicate a dynamic and evolving landscape within the US Neuropathic Pain Market, focusing on improving patients’ quality of life through innovative and effective solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Neuropathic Pain Market Drivers**

### **Rising Prevalence of Diabetes and Related Neuropathic Conditions**

In the United States, diabetes is a significant contributor to neuropathic pain, with an estimated 34.2 million Americans affected by diabetes, according to the Centers for Disease Control and Prevention (CDC). Approximately 60% to 70% of people with diabetes suffer from some form of neuropathy, which translates to around 20 million individuals experiencing diabetic neuropathy. This increasing prevalence of diabetes directly drives demand for treatments in the US Neuropathic Pain Market Industry.

Organizations like the American Diabetes Association have reported a growing incidence of type 2 diabetes due to rising obesity rates, highlighting the urgency in developing therapeutic solutions to manage related neuropathic pain effectively. The rising number of patients needing management for neuropathic pain will contribute significantly to market growth and enhancement of treatment options.

### **Advancements in Pain Management Therapies**

The US Neuropathic Pain Market Industry is witnessing an influx of innovative treatment options, including novel pharmacological therapies and minimally invasive procedures. According to the American Society of Pain and Neuroscience, advancements in Research and Development (R&D) of neuromodulators and other drug classifications are expected to enhance pain management and offer new hope to patients who have previously exhausted standard treatment protocols.

Clinical trials for new drugs in recent years have surged, aiming to develop effective analgesics that target specific neuropathic mechanisms, which will inject vitality into the overall market. This continuous evolution in treatment through R&D initiatives is crucial for attracting investment and improving patient outcomes.

### **Growing Geriatric Population in the United States**

As reported by the Administration for Community Living, the percentage of Americans aged 65 years and older is projected to rise from 16% in 2020 to 21% by 2030. Older adults are particularly vulnerable to neuropathic pain due to multiple chronic diseases prevalent in this demographic, such as cancer and diabetes. This growing elderly population will significantly impact the US Neuropathic Pain Market Industry as it necessitates adaptations in healthcare services and pain management strategies.

A robust increase in healthcare expenditure for the elderly, as highlighted by the Medicare Program, indicates that healthcare providers will need to prioritize neuropathic pain therapies tailored for this age group, thus driving sustained market growth.

### **Enhanced Awareness and Education on Neuropathic Pain**

In recent years, there has been a notable increase in campaigns aimed at raising awareness about neuropathic pain and its impact on quality of life. Organizations like the Neuropathy Association have led initiatives to educate both healthcare providers and patients. This greater awareness contributes to early diagnosis and treatment, which is critical for effective pain management.

The National Institutes of Health (NIH) have emphasized the importance of educational programs in understanding neuropathic pain, suggesting that improved awareness can lead to significant advancements in patient care and investment in new therapies. Consequently, this enhanced educational outreach serves as a significant driver for growth within the US Neuropathic Pain Market Industry, as it encourages more individuals to seek help and explore available treatment options.

## **US Neuropathic Pain Market Segment Insights**

### **Neuropathic Pain Market Type of Neuropathic Pain Insights**

The US Neuropathic Pain Market has shown substantial growth, driven by an increasing prevalence of chronic pain conditions and the growing awareness of neuropathic pain among healthcare professionals. This segment is characterized by various types of neuropathic pain, each impacting a different patient demographic and requiring tailored treatment approaches. Diabetic Neuropathy is notably significant, linked to the heightened incidence of diabetes in the US, which affects millions, thereby contributing to a considerable patient population suffering from neuropathic symptoms affecting their quality of life.

Another critical type is Postherpetic Neuralgia, which results as a complication from shingles; its importance is underscored by the increasing number of older adults in the US, as this demographic is more susceptible to shingles and its lingering pain effects. Trigeminal Neuralgia, another major type, is recognized for its intense facial pain, presenting a significant challenge for diagnosis and treatment, compelling advancements in pain management solutions.

Lastly, Chemotherapy-Induced Peripheral Neuropathy, a distressing side effect of cancer treatments, has gained recognition as awareness of the side effects of chemotherapy increases; this segment is particularly crucial as it can hinder effective cancer treatment adherence and affect survival rates.

The drivers of growth in the US Neuropathic Pain Market include a rising geriatric population, innovative drug formulations, and ongoing research and development activities focused on neuropathic pain management therapies. However, challenges persist, such as high treatment costs, variation in patient responses to pain management therapies, and the frequent need for multi-modal treatment approaches. The overall market displays a dynamic interplay of various types of neuropathic pain, each holding its unique significance and demand for focused treatment development in the rapidly evolving US healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neuropathic Pain Market Treatment Type Insights**

The Treatment Type segment of the US Neuropathic Pain Market illustrates a comprehensive approach to managing neuropathic pain challenges. This market segment encompasses various methodologies, including Medications, Physical Therapy, Surgical Procedures, and Electrical Stimulation. Medications remain a crucial approach, leveraging advancements in pharmaceuticals to address neuropathic pain symptoms effectively, catering to a diverse patient demographic. Physical Therapy provides a vital role in rehabilitative strategies, emphasizing movement and strengthening techniques that are essential in improving quality of life.

Surgical Procedures, while less commonly employed, serve as a significant intervention for chronic and intractable cases, offering potential relief when other treatments fail. Meanwhile, Electrical Stimulation has garnered attention for its non-invasive nature, delivering pain relief through innovative technological solutions. The US Neuropathic Pain Market statistics reflect a growing preference for multimodal approaches, with healthcare providers increasingly recognizing the benefits of combining these treatment types to enhance patient outcomes and overall satisfaction. The ongoing advancements in treatment technologies, coupled with an aging population, contribute to a robust landscape for growth and innovation within this market segment.

Consequently, the Treatment Type segment not only addresses the pressing needs of neuropathic pain sufferers but also aligns with broader trends in personalized medicine and comprehensive pain management strategies.

### **Neuropathic Pain Market Route of Administration Insights**

The Route of Administration segment within the US Neuropathic Pain Market plays a crucial role in how therapeutic agents are delivered to patients. The market has seen notable growth driven by the increasing prevalence of neuropathic pain conditions such as diabetic neuropathy, postherpetic neuralgia, and other nerve-related disorders. Each method of administrationoral, topical, and injectableoffers unique advantages, influencing patient adherence and healthcare outcomes. Oral administration remains a common choice due to its ease of use and widespread acceptance among patients.

Topical formulations are gaining traction, especially among individuals seeking localized relief with minimal systemic effects, thereby enhancing patient comfort and compliance. Injectable therapies, though often utilized for more acute or severe pain conditions, provide rapid relief and can be crucial in managing breakthrough pain. 
Overall, the diversity in routes of administration contributes significantly to the ongoing innovation in the US Neuropathic Pain Market, addressing unique patient needs and expanding treatment options. Enhanced awareness, education, and advancements in formulation technologies are likely to foster further growth in this segment, aligning with the broader market trends towards personalized medicine and patient-centered care.

### **Neuropathic Pain Market End User Insights**

The US Neuropathic Pain Market is significantly influenced by its End User segment, which primarily consists of Hospitals, Clinics, and Home Care. Hospitals play a crucial role as they are key providers of acute pain management services and are equipped with advanced technologies and specialists for comprehensive treatment. Clinics, on the other hand, often provide outpatient services and are essential for ongoing patient care and monitoring, offering a more personalized approach that caters to individual patient needs.

Home Care has gained traction, particularly due to the rising emphasis on patient-centered treatment, providing comfort and familiar surroundings for individuals with neuropathic pain. This segment addresses not only clinical needs but also offers psychological benefits, as patients engage in familiar environments during recovery. Each of these End User categories has unique characteristics and growing importance within the US Neuropathic Pain Market, with trends indicating a shift towards more integrated care models that enhance patient accessibility and improve outcomes.

The increasing prevalence of chronic diseases and the aging population in the US are key growth drivers that make understanding the segmentation of the market vital for future planning and resource allocation.

## **US Neuropathic Pain Market Key Players and Competitive Insights**

The US Neuropathic Pain Market is characterized by a diverse and intensely competitive landscape. As the prevalence of neuropathic pain continues to rise, driven by factors such as diabetes, shingles, and chemotherapy, multiple companies are vying for a stronger foothold in this lucrative sector. The market includes both established pharmaceutical giants and emerging players, each striving to differentiate themselves through innovative treatments and therapies. Companies are investing in research and development to introduce advanced pharmacological solutions, while also focusing on strategic collaborations and partnerships to enhance their product offerings.

Furthermore, the landscape is influenced by changing regulatory frameworks and the increasing demand for personalized medicine, making it crucial for organizations to stay agile and responsive to market needs.

Bristol Myers Squibb has a notable presence in the US Neuropathic Pain Market, leveraging its extensive portfolio of medications and therapeutic options. The company is well-recognized for its commitment to addressing complex pain conditions through robust clinical research and innovative drug formulations. Its strengths include a strong emphasis on patient-centric approaches and a solid pipeline of potential treatments that may enhance the quality of life for individuals suffering from neuropathic pain.

By focusing on strategic partnerships and collaborations, Bristol Myers Squibb has positioned itself to effectively cater to the evolving needs of healthcare providers and patients alike, establishing itself as a competitive player in this market.

Novartis is another significant entity within the US Neuropathic Pain Market, known for its comprehensive range of products aimed at alleviating neuropathic pain symptoms. The company has developed several key medications that target different aspects of neuropathic pain, enhancing its market presence and providing physicians with diverse treatment options. Novartis's strengths lie in its strong commitment to innovation, evidenced by ongoing investments in research and development aimed at improving existing therapies and pioneering new ones. The company has also engaged in strategic mergers and acquisitions, bolstering its capabilities and expanding its footprint within the US market.

Through these initiatives, Novartis continues to solidify its reputation as a leader in addressing neuropathic pain, ensuring that it remains a formidable competitor in this dynamic industry.

### **Key Companies in the US Neuropathic Pain Market Include**

## **US Neuropathic Pain Market Industry Developments**

Recent developments in the US Neuropathic Pain Market have been significant, with various pharmaceutical companies making strides in Research and Development. Bristol Myers Squibb and Eli Lilly are actively engaged in enhancing treatment options for neuropathic pain, focusing on innovative mechanisms of action. As of October 2023, major companies like Pfizer and AbbVie have reported growth in market valuation, positively influencing the competitive landscape.

In terms of mergers and acquisitions, Amgen announced the acquisition of Horizon Therapeutics in September 2023, which has a strong focus on pain management therapies, further consolidating its position in the market. Moreover, Novartis launched a new clinical trial aimed at targeting chronic neuropathic pain, emphasizing the evolving treatment paradigms. Notable advancements in the last two years also include Teva Pharmaceutical's efforts to expand its generics portfolio for neuropathic pain medications, thereby ensuring affordability and wider accessibility.

The increasing prevalence of diabetic neuropathy adds pressure on companies to innovate, reflecting an urgent need for effective pain management solutions, as the National Institutes of Health reported a rise in cases, driving the demand for novel therapies.

## **US Neuropathic Pain Market Segmentation Insights**

### **Neuropathic Pain Market Type of Neuropathic Pain Outlook**

### **Neuropathic Pain Market Treatment Type Outlook**

### **Neuropathic Pain Market Route of Administration Outlook**

### **Neuropathic Pain Market End User Outlook**

## Market Drivers

### Growing Geriatric Population

The aging population in the US is a significant factor influencing the neuropathic pain market. As individuals age, they become more susceptible to various neuropathic conditions, including diabetic neuropathy and post-surgical pain. The US Census Bureau projects that by 2030, approximately 20% of the population will be aged 65 and older, which correlates with an increased prevalence of neuropathic pain. This demographic shift is likely to drive demand for effective pain management solutions, thereby expanding the neuropathic pain market. Healthcare systems will need to adapt to this growing need, potentially leading to increased investment in research and treatment options tailored for older adults.

### Increased Awareness and Diagnosis

There is a notable increase in awareness regarding neuropathic pain and its associated conditions among both healthcare professionals and the general public. Enhanced education and training for clinicians have led to improved diagnostic capabilities, allowing for earlier identification of neuropathic pain. This trend is crucial as timely diagnosis can significantly impact treatment outcomes. The neuropathic pain market benefits from this heightened awareness, as more patients seek medical attention for their symptoms. Furthermore, the implementation of standardized diagnostic criteria has facilitated better recognition of neuropathic pain, potentially increasing the market size as more individuals are diagnosed and treated.

### Regulatory Support for Pain Management

Regulatory bodies in the US are increasingly recognizing the importance of effective pain management, which is positively impacting the neuropathic pain market. Initiatives aimed at improving access to pain relief therapies, including streamlined approval processes for new medications, are being implemented. The Food and Drug Administration (FDA) has been actively involved in promoting research and development of innovative pain management solutions. This regulatory support is likely to enhance the availability of effective treatments for neuropathic pain, thereby fostering market growth. As regulations evolve to support better pain management practices, the neuropathic pain market is expected to benefit from increased investment and innovation.

### Advancements in Pharmaceutical Research

Ongoing advancements in pharmaceutical research are driving innovation within the neuropathic pain market. The development of new analgesics, including novel classes of medications such as cannabinoids and gene therapies, is expanding treatment options for patients. Recent studies indicate that the neuropathic pain market could reach a valuation of approximately $5 billion by 2027, driven by these innovative therapies. Additionally, the focus on understanding the underlying mechanisms of neuropathic pain is likely to yield more effective treatments, further stimulating market growth. As pharmaceutical companies invest in research and development, the landscape of available therapies is expected to evolve, providing patients with more choices.

### Rising Prevalence of Neuropathic Disorders

The increasing incidence of neuropathic disorders in the US is a primary driver for the neuropathic pain market. Conditions such as diabetic neuropathy, postherpetic neuralgia, and multiple sclerosis are becoming more common, affecting millions of individuals. According to recent estimates, approximately 7-10% of the US population suffers from neuropathic pain, which translates to around 20 million people. This growing patient population necessitates the development and availability of effective treatment options, thereby propelling the neuropathic pain market forward. As healthcare providers seek to address this rising demand, the industry is likely to witness significant growth in both pharmaceutical and non-pharmaceutical interventions, including novel analgesics and alternative therapies.

## Future Outlook

The [Neuropathic Pain Market](https://www.marketresearchfuture.com/reports/neuropathic-pain-market-1390) is projected to grow at a 6.76% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness.

**New opportunities:**

- Development of telehealth platforms for remote pain management solutions. Investment in AI-driven diagnostics for personalized treatment plans. Expansion of over-the-counter neuropathic pain relief products in retail pharmacies.

By 2035, the neuropathic pain market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type of Neuropathic Pain: Diabetic Neuropathy (Largest) vs. Postherpetic Neuralgia (Fastest-Growing)

In the US neuropathic pain market, the segment of Diabetic Neuropathy holds the largest market share, largely due to the rising incidence of diabetes and the significant number of patients experiencing neuropathic complications. Following closely is Postherpetic Neuralgia, which is witnessing impressive growth as awareness and diagnosis improve, alongside treatment advancements. Trigeminal Neuralgia and Chemotherapy-Induced Peripheral Neuropathy also contribute to the market but remain smaller in comparison.

The growth trends for these segments are influenced by several key factors. The increasing prevalence of diabetes and related conditions drives the demand for effective management of Diabetic Neuropathy. Meanwhile, Postherpetic Neuralgia is gaining traction due to the aging population and the impact of shingles. Moreover, ongoing research and development in new treatment modalities are expected to further boost growth in these segments, with improvements in patient outcomes being a significant driver.

Diabetic Neuropathy (Dominant) vs. Postherpetic Neuralgia (Emerging)

Diabetic Neuropathy is currently the dominant segment in the US neuropathic pain market, characterized by long-term complications arising from diabetes leading to significant nerve damage. Patients commonly experience symptoms such as pain, numbness, and tingling, prompting a critical need for effective treatment options, which have evolved significantly in recent years. In contrast, Postherpetic Neuralgia is emerging rapidly, particularly due to its association with herpes zoster infection. This segment is distinguished by its chronic pain lasting long after the rash has cleared, affecting quality of life. The healthcare sector is responding to these needs through innovative therapies and comprehensive pain management strategies, enhancing the profiles of both conditions in the market.

### By Treatment Type: Medications (Largest) vs. Electrical Stimulation (Fastest-Growing)

In the treatment type segment of the US neuropathic pain market, medications hold the largest market share due to their widespread acceptance and varied formulations, which appeal to a broad range of patients. Physical therapy and surgical procedures follow, each capturing unique patient bases with specific requirements. Conversely, electrical stimulation is rapidly gaining traction as a modern alternative that aligns with current healthcare trends emphasizing non-invasive solutions.

Growth trends indicate that the US neuropathic pain market is witnessing a shift towards personalized and multidisciplinary approaches to treatment. Medications continue to evolve with new formulations and delivery methods, while electrical stimulation technologies are emerging as a safe, effective choice. Increased awareness, advancements in technology, and a growing focus on holistic care are substantial drivers of growth, particularly in the electrical stimulation segment.

Medications (Dominant) vs. Electrical Stimulation (Emerging)

Medications for neuropathic pain are characterized by their established efficacy and a wide range of options, including opioids, anticonvulsants, and antidepressants. This segment is well-supported by clinical guidelines and has become the first line of treatment for many patients. In contrast, electrical stimulation represents an emerging methodology, focusing on non-pharmacological interventions. This approach offers patients a viable alternative, particularly when traditional medications fail or lead to undesirable side effects. The growing body of clinical evidence supporting electrical stimulation, along with increasing investments in technological advancements, positions it as a rapidly growing segment that complements traditional medication approaches.

### By Route of Administration: Oral (Largest) vs. Topical (Fastest-Growing)

In the US neuropathic pain market, the route of administration segment comprises three main categories: Oral, Topical, and Injectable. Oral administration holds the largest share due to its widespread acceptance, convenience, and ease of dosing. On the other hand, Topical administration, while smaller in share, is rapidly gaining popularity as it offers targeted relief with reduced systemic effects. Injectable administration, though less common, plays a crucial role in severe pain management where immediate relief is necessary.

Recent growth trends indicate a significant shift towards non-invasive options such as Topical formulations, driven by patient preference for ease and fewer side effects. Innovations in drug delivery methods are enhancing the efficacy of Topical and Injectable treatments. Additionally, the rising prevalence of neuropathic pain conditions and increased awareness about effective pain management strategies are key factors fueling the growth of these segments in the market.

Oral (Dominant) vs. Topical (Emerging)

The Oral route of administration remains dominant in the US neuropathic pain market, primarily due to its familiarity among patients and healthcare providers. It enables easy self-administration and has a wide range of formulations available, which contributes to patient compliance. In contrast, the Topical route is emerging as a favorable alternative, especially for patients seeking localized relief without systemic exposure. The advancements in transdermal technologies are improving the absorption and efficacy of Topical products, making them increasingly attractive for managing neuropathic pain. As patient-centric care becomes integral to pain management, the competition between Oral and Topical routes will intensify, leading to a more dynamic market landscape.

### By End User: Hospitals (Largest) vs. Home Care (Fastest-Growing)

In the US neuropathic pain market, hospitals represent the largest segment in the end user category, driven by their comprehensive resources and ability to provide advanced care for complex pain conditions. Clinics also hold a significant share, catering to outpatient needs and offering specialized services, while home care has emerged as a growing segment, appealing to patients seeking convenience and personalized management of neuropathic pain.

The growth trends within this segment are largely influenced by the increasing prevalence of neuropathic pain, coupled with a rise in awareness about pain management strategies. Home care is particularly gaining traction due to the aging population and advancements in telehealth, allowing for better patient monitoring and support in non-hospital settings. The demand for more accessible, flexible care solutions is expected to drive further growth in this segment.

Hospitals (Dominant) vs. Home Care (Emerging)

Hospitals serve as the dominant end user in the US neuropathic pain market, offering extensive treatment options and multi-disciplinary approaches. They provide access to specialized medical professionals and advanced technology needed for diagnosis and treatment. In contrast, the home care segment is emerging rapidly as it addresses the needs of patients preferring home management of their conditions. This shift is facilitated by increased patient uptake of digital health solutions and a growing emphasis on personalized care. Both segments complement each other, with hospitals handling severe cases and home care supporting ongoing management, highlighting the evolving landscape of neuropathic pain treatment.

## Competitive Benchmarking

the neuropathic pain market is characterized by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), Eli Lilly and Company (US), and AbbVie Inc (US) are actively engaged in enhancing their product portfolios and expanding their market reach. Pfizer Inc (US) has been focusing on the development of novel therapies that target specific neuropathic pain pathways, which appears to position the company favorably in a market that demands precision medicine. Meanwhile, Eli Lilly and Company (US) has been pursuing strategic collaborations with technology firms to integrate digital health solutions into their treatment offerings, thereby enhancing patient engagement and adherence. AbbVie Inc (US) is also investing in research and development to innovate its existing pain management products, indicating a collective trend among these companies to leverage advanced technologies and partnerships to strengthen their competitive edge.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure of the neuropathic pain market is moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they often set the pace for innovation and market trends. This dynamic creates a competitive environment where smaller firms may struggle to keep up with the rapid advancements and strategic maneuvers of larger entities.
In October Pfizer Inc (US) announced a collaboration with a leading biotech firm to develop a new class of pain relief medications that target neuropathic pain more effectively. This strategic move is likely to enhance Pfizer's portfolio and could potentially lead to breakthroughs in treatment efficacy, thereby solidifying its position in the market. Similarly, in September 2025, Eli Lilly and Company (US) launched a digital platform aimed at providing personalized pain management solutions, which may significantly improve patient outcomes and adherence to treatment regimens. This initiative reflects a growing trend towards integrating technology into healthcare, which could reshape patient experiences in the neuropathic pain sector.
In August AbbVie Inc (US) expanded its research capabilities by acquiring a small pharmaceutical company specializing in neuromodulation therapies. This acquisition is indicative of AbbVie's commitment to diversifying its pain management offerings and underscores the importance of innovation in maintaining competitive advantage. Furthermore, in July 2025, Teva Pharmaceutical Industries Ltd (IL) announced a partnership with a tech startup to develop AI-driven solutions for pain assessment and management, which may enhance the precision of treatment plans and improve patient care.
As of November the competitive trends in the neuropathic pain market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift may ultimately lead to a more patient-centric approach in the neuropathic pain market, where companies that prioritize innovation and technology are likely to thrive.

## Recent News & Developments

Recent developments in the US Neuropathic Pain Market have been significant, with various pharmaceutical companies making strides in Research and Development. Bristol Myers Squibb and Eli Lilly are actively engaged in enhancing treatment options for neuropathic pain, focusing on innovative mechanisms of action. As of October 2023, major companies like Pfizer and AbbVie have reported growth in market valuation, positively influencing the competitive landscape.

In terms of mergers and acquisitions, Amgen announced the acquisition of Horizon Therapeutics in September 2023, which has a strong focus on pain management therapies, further consolidating its position in the market. Moreover, Novartis launched a new clinical trial aimed at targeting chronic neuropathic pain, emphasizing the evolving treatment paradigms. Notable advancements in the last two years also include Teva Pharmaceutical's efforts to expand its generics portfolio for neuropathic pain medications, thereby ensuring affordability and wider accessibility.

The increasing prevalence of diabetic neuropathy adds pressure on companies to innovate, reflecting an urgent need for effective pain management solutions, as the National Institutes of Health reported a rise in cases, driving the demand for novel therapies.

## Report Scope

| MARKET SIZE 2024 | 1911.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2040.18(USD Million) |
| MARKET SIZE 2035 | 3926.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.76% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc (US), Eli Lilly and Company (US), Astellas Pharma Inc (JP), Boehringer Ingelheim GmbH (DE), Teva Pharmaceutical Industries Ltd (IL), Novartis AG (CH), Johnson & Johnson (US), AbbVie Inc (US) |
| Segments Covered | Type of Neuropathic Pain, Treatment Type, Route of Administration, End User |
| Key Market Opportunities | Advancements in digital therapeutics and personalized medicine enhance treatment options in the neuropathic pain market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the neuropathic pain market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US neuropathic pain market?**
A: The market valuation was $1911.0 Million in 2024.

**Q: What is the projected market size for the US neuropathic pain market by 2035?**
A: The projected valuation for 2035 is $3926.0 Million.

**Q: What is the expected CAGR for the US neuropathic pain market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.76% during the forecast period.

**Q: Which companies are the key players in the US neuropathic pain market?**
A: Key players include Pfizer Inc, Eli Lilly and Company, Astellas Pharma Inc, and others.

**Q: What segment of neuropathic pain had the highest valuation in 2024?**
A: Diabetic Neuropathy had the highest valuation at $800.0 Million.

**Q: What treatment type is projected to have significant growth in the US neuropathic pain market?**
A: Medications are projected to grow significantly, with a valuation range of $800.0 Million to $1600.0 Million.

**Q: How does the valuation of electrical stimulation compare to other treatment types?**
A: Electrical Stimulation had a valuation range of $411.0 Million to $926.0 Million.

**Q: What is the expected market performance for injectable routes of administration?**
A: Injectable routes are projected to have a valuation range of $511.0 Million to $1126.0 Million.

**Q: Which end user segment is anticipated to dominate the US neuropathic pain market?**
A: Hospitals are expected to dominate, with a valuation range of $800.0 Million to $1600.0 Million.

**Q: What is the projected growth trend for clinics in the US neuropathic pain market?**
A: Clinics are projected to have a valuation range of $600.0 Million to $1200.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-neuropathic-pain-market-19470*